Evidence map›Paper›PMID 41590335›Full record

ArticleCurrent oncology (Toronto, Ont.)2025

The Canadian Breast Cancer Symposium 2025: Meeting Report.

Christine Brezden-Masley, Katarzyna J Jerzak, Nancy A Nixon, Anne Koch, Amanda Roberts, Jean-François Boileau, May Lynn Quan, M J DeCoteau, Tulin D Cil

Abstract readConference Proceedings
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Christine Brezden-MasleyMarvelle Koffler Breast Centre, Mount Sinai Hospital, University of Toronto, Toronto, ON M5G 1X5, Canada.ORCID 0000-0002-4818-318X
Katarzyna J JerzakSunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON M4N 3M5, Canada.
Nancy A NixonDepartment of Surgery and Oncology, University of Calgary, Calgary, AB T2N 4Z6, Canada.
Anne KochPrincess Margaret Cancer Centre, Toronto, ON M5G 2M9, Canada.
Amanda RobertsSunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON M4N 3M5, Canada.ORCID 0000-0002-0153-0316
Jean-François BoileauJewish General Hospital, Montreal, QC H3T 1E2, Canada.
May Lynn QuanDepartment of Surgery and Oncology, University of Calgary, Calgary, AB T2N 4Z6, Canada.
M J DeCoteauRethink Breast Cancer, Toronto, ON M4M 3G3, Canada.
Tulin D CilPrincess Margaret Cancer Centre, Toronto, ON M5G 2M9, Canada.

Funding

Astra Zeneca naBeone naEli Lilly (Canada) naExact Sciences naGilead Sciences (Canada) naHoffmann-La Roche naHologic naMDPI naMerck naMerit Medical naNovartis naPfizer naStryker naUniversity of Toronto na
6 · The paper itself

Abstract

The 2025 Canadian Breast Cancer Symposium (CBCS) brought together patients, clinicians and researchers from across Canada to discuss advances shaping personalized breast cancer care. Key updates in systemic therapy highlighted expanding treatment options, including CDK4/6 inhibitors, oral SERDs, PI3K/AKT-targeted therapies, and antibody-drug conjugates across early and metastatic settings. Radiation oncology sessions emphasized treatment de-escalation, featuring evidence for ultra-hypofractionation, selective omission of nodal irradiation, and stereotactic strategies to manage oligoprogression. Surgical presentations focused on reducing morbidity through tailored axillary management and emerging techniques to prevent lymphedema. Advances in the management of central nervous system metastases underscored the growing synergy between stereotactic radiotherapy and CNS-active systemic therapies. Informed by patient testimony and advocacy perspectives, experts reflected on persistent gaps in diagnosis, access, and survivorship that shape priorities for future improvements. Together, these insights outline key directions that help to refine clinical practice and guide future research.

Indexed as

Breast NeoplasmsCanadaFemaleHumansbreast cancerCNS metastasesnew advancespatient voicesurgical oncologysystemic therapy

Identifiers

PMID41590335
PMCPMC12839805

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.